Table 1.
Baseline characteristics of the randomised patients
| Characteristic | Eradication (Group HpE) (n = 53) | Placebo (Group Hp+) (n = 51) | p Value |
| Age (y)* | 54.0 (13.8) | 53.0 (14.9) | 0.81 |
| Male (%) | 26 (49.1) | 23 (45.1) | 0.69 |
| Current cigarette use (%) | 7 (13.2) | 10 (19.6) | 0.38 |
| Alcohol consumption (%) | 10 (18.9) | 10 (19.6) | 0.92 |
| Body mass index* | 24.7 (3.8) | 23.4 (3.4) | 0.7 |
| Grading of oesophagitis (%) (modified Savary Miller) | |||
| 0 | 38 (71.7) | 35 (68.6) | |
| 1–2 | 14 (26.4) | 14 (27.5) | 0.81 |
| 3–4 | 1 (1.9) | 2 (3.9) | |
| Hiatus hernia (%) | 10 (18.9) | 9 (17.6) | 0.87 |
| Prevalence of CagA positivity (%) | 70 | 75 | 0.59 |
| Previous use of proton pump inhibitor (%) | 3 (5.7) | 2 (3.9) | 1.0 |
| Symptom score (%) | |||
| 1 | 15 (28.3) | 20 (39.2) | |
| 2 | 29 (54.7) | 28 (54.9) | 0.10 |
| 3 | 9 (17) | 3 (5.9) | |
| Symptom duration (%) | |||
| 1 y | 17 (32.1) | 22 (43.1) | |
| >1–5 y | 23 (43.4) | 16 (31.4) | 0.57 |
| >5–10 y | 5 (9.4) | 4 (7.8) | |
| >10 y | 8 (15.1) | 9 (17.6) | |
*Values are mean (SD).